factual

Cycle Exposure Driven By Pharma Spending Swings

The primary cyclical risk is pharmaceutical spending, since Agilent struggles when its largest pharma customers pull back, and it is not heavily reliant on US government funding, with academia and government under 10% of sales and NIH-related funding only about 1%.

factualpending

Speaker

Marc

Evidence Quote

“And actually the NIH related funding, which is the one that's particularly under pressure, that's only about 1% of their sales.”

Source

Agilent: Back To The Lab— Business Breakdowns
Created: 11/12/2026, 11:55:35 AM

Your notes

Loading notes...